Our Partnership
Key Structures
Topics
Results & Data
Impact Stories
-
30 August 2022Suzy’s Fight: Eliminating Malaria Despite COVID-19 and Deadly Storms
-
18 August 2022Ukraine: Ensuring Life-Saving Tuberculosis Care Amidst Deadly Conflict
-
08 August 2022Tanzania's First Line of Defense Against Pandemics
-
26 July 2022An HIV Peer Educator Lights a Fuse for Girls in Her Community
News Releases
-
22 September 2022
The Global Fund Signs Agreement with Pfizer to Expand Access to PAXLOVID™ Antivi…
-
21 September 2022
Global Fund Private Sector Partners Pledge Record Levels of Support to End AIDS,…
-
21 September 2022
Global Fund Partners Pledge Record Level of Support to End Deadly Diseases, Prev…
-
20 September 2022
Global Fund Approves Emergency Funding to Help Maintain Essential Health Service…
Opinion
-
21 September 2022
Why the World Can’t Afford to Give HIV, TB and Malaria a Chance to Bounce Back
-
01 September 2022
Dr. Donald Kaberuka “We can put an end to HIV-AIDS by 2030”
-
30 August 2022
Funding Healthcare Abroad Can Protect Britain From the Next Pandemic
-
19 August 2022
Monkeypox, Marburg and Miserable Heat: How the World Should Respond to Intersect…
Updates
Featured
GF/B13/DP29
Approved by the Board on: 28 April 2006
Phase 2 Nigeria Grants (NGA-102-G01-H-00; NGA-102-G03-H-00)
Decision Point 1:
The Board declines to approve additional funding for the Phase 2 period of the Nigeria Grant number NGA-102-G01-H-00 (Expansion of Prevention of Mother to Child Centers of Excellence).
Decision Point 2:
The Board declines to approve additional funding for the Phase 2 period of the Nigeria Grant number NGA-102-G03-H-00 (Program for the expansion of anti-retroviral therapy in Nigeria).
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.